Last reviewed 2026-04-22 · How we verify

BBV154(Intranasal) & covaxin

BBV154 is an intranasal booster vaccine designed to enhance immune response against SARS-CoV-2 when administered after Covaxin (inactivated COVID-19 vaccine) priming.

BBV154 is an intranasal booster vaccine designed to enhance immune response against SARS-CoV-2 when administered after Covaxin (inactivated COVID-19 vaccine) priming. Used for COVID-19 prevention as a booster dose in Covaxin-primed individuals.

At a glance

Mechanism of action

BBV154 delivers viral antigens via the intranasal route to stimulate mucosal and systemic immunity, complementing the intramuscular Covaxin primary series. This heterologous prime-boost strategy aims to broaden and strengthen neutralizing antibody responses and T-cell immunity against COVID-19, potentially improving protection against emerging variants.

Approved indications

• COVID-19 prevention as a booster dose in Covaxin-primed individuals

Common side effects

• Nasal congestion or rhinitis
• Headache
• Fatigue
• Myalgia
• Local nasal irritation

Key clinical trials

• BBV152/BBV154 Heterologus Prime-Boost Study (PHASE2)
• Phase 3 Study to Evaluate Immunogenicity and Safety of BBV154 Booster Dose (PHASE3)
• Phase III Study of BBV154 Intranasal Vaccine in Healthy Volunteers (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• BBV154(Intranasal) & covaxin CI brief — competitive landscape report
• BBV154(Intranasal) & covaxin updates RSS · CI watch RSS
• Bharat Biotech International Limited portfolio CI